112 results
424B5
MREO
Mereo Biopharma Group Plc
14 Jun 24
Prospectus supplement for primary offering
4:15pm
disruptions;
public concern relating to the commercial value or safety of our product candidates;
financing or other corporate transactions;
publication
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
11 Jun 24
Regulation FD Disclosure
9:15pm
product candidates in clinical development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety and efficacy … , business plans and objectives for UX143, expectations regarding the tolerability and safety of UX143, and future clinical and regulatory
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
, including but not limited to failed studies, complex results, safety issues, or other regulatory challenges.
We expect that our existing cash … Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
-term safety and efficacy data from the Phase 2 portion of the Orbit study are expected in the second half of 2024.
The Cosmic study was initiated … product candidates in clinical development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety and efficacy
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
which time he was involved in the safety and efficacy review of hundreds of drugs. Most recently Dr. Shames served as Deputy Director, Office of Drug
10-K
skvp 4ihil0s4901
27 Mar 24
Annual report
5:20pm
10-K
EX-10.30
absua7d
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
nw4vm07n2vqfifu
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
t3vjrjqhf1 mn5s1pq
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-3.1
khn56luknrhuijr7nk
18 Dec 23
Current report (foreign)
4:10pm
6-K
EX-99.1
cvfnn
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.1
mf7hpdqnx8d
17 Oct 23
Current report (foreign)
7:01am
6-K
p9pnerdnzwp
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.3
ck2g1z7o
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
5u5ubkpm p6
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
edrou8n w4eio0mq2lt
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
EX-99.1
tutgtblm9
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
6ao6e08l w4q4ur5lz
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
dxi8le
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.2
uayrh
2 Nov 22
Current report (foreign)
4:17pm